Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva to Present at the BofA Securities Health Care Conference

Selasa, 05 Mei 2026 - 22:17:45 Wib
Globenewswire

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Kamis, 30 April 2026 - 23:31:17 Wib
Globenewswire

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Rabu, 29 April 2026 - 23:07:43 Wib
Globenewswire

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Rabu, 29 April 2026 - 23:06:45 Wib
Globenewswire

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Rabu, 15 April 2026 - 21:53:02 Wib
Globenewswire

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Selasa, 14 April 2026 - 21:12:27 Wib
Globenewswire

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Senin, 30 Maret 2026 - 22:26:49 Wib
Globenewswire

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

Rabu, 04 Maret 2026 - 05:40:38 Wib
Globenewswire

Teva to Present at the Upcoming Investor Conferences in March

Rabu, 25 Februari 2026 - 06:28:43 Wib
Globenewswire

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Senin, 23 Februari 2026 - 11:54:59 Wib
Globenewswire

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Kamis, 19 Februari 2026 - 20:10:05 Wib
Globenewswire

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Rabu, 28 Januari 2026 - 22:28:49 Wib
Globenewswire

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Selasa, 27 Januari 2026 - 22:09:08 Wib
Globenewswire

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Kamis, 15 Januari 2026 - 20:12:04 Wib
Globenewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Selasa, 13 Januari 2026 - 05:49:02 Wib
Globenewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Selasa, 13 Januari 2026 - 05:45:26 Wib
Globenewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rabu, 07 Januari 2026 - 05:44:13 Wib
Globenewswire

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Rabu, 24 Desember 2025 - 21:43:13 Wib
Globenewswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Jumat, 19 Desember 2025 - 23:24:52 Wib
Globenewswire

Teva Releases Q4 2025 Aide Memoire

Sabtu, 13 Desember 2025 - 18:19:47 Wib
Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Sabtu, 13 Desember 2025 - 18:19:12 Wib
Globenewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Kamis, 11 Desember 2025 - 00:07:40 Wib
Globenewswire

Teva Receives European Commission Approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Rabu, 26 November 2025 - 04:34:43 Wib
Globenewswire

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Ahad, 23 November 2025 - 03:32:24 Wib
Globenewswire

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

Rabu, 19 November 2025 - 20:34:20 Wib